The first day of the IPO subscription for Lemedi concluded around 4 p.m. on the 1st. The subscription, led by KB Securities, drew intense interest with a total of 122,170 applications on the first day. Based on the first day's results, the equally allocated shares were tallied at 1.23 shares based on the minimum subscription quantity, and the proportional competition rate stood at 95.82 to 1.

What kind of company is Lemedi?

According to regulatory filings, Lemedi is a specialized company that develops, manufactures, and sells portable X-ray imaging devices and non-destructive testing solutions for use in medical and industrial fields, based on its independently developed low-dose, miniaturized X-ray generation and control technology platform. Its flagship products include the 'KA6' and 'XCAM series,' which are portable digital X-ray imaging devices for medical use, as well as non-destructive testing (NDT) equipment for industrial applications.

Listing scheduled for July 13... 82,800 won possible with a triple

Meanwhile, Lemedi is set to list on July 13. The IPO price is 27,000 won. If the stock records a 'triple,' surging 300% compared to the IPO price on the listing day, the share price could soar to 82,800 won.

[This article is by no means an investment recommendation. The content may merely reflect opinions, so please do not use it as a reference or data for investment. All investments are made at the individual's own discretion, and the final responsibility lies with the investor. This publication assumes no responsibility whatsoever.]